Results 121 to 130 of about 42,337 (292)

A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes [PDF]

, 1994
Sucha Nand, Jeff Sosman, John E. Godwin, RI Fisher   +3 more
openalex   +1 more source

Sensitization of Non‐M3 Acute Myeloid Leukemia Blasts to All‐Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study

European Journal of Haematology, EarlyView.
ABSTRACT The treatment of elderly, nonfit acute myeloid leukemia (AML)/MDS patients with relapsed/refractory (R/R) disease remains challenging. As histone demethylase LSD1 (KDM1A) is a rational therapeutic target in AML, we conducted a phase I trial (“rolling‐six design”) with the LSD1 inhibitor tranylcypromine (TCP, dose levels [DL] 20, 40, 60, 80 mg ...
Michael Kruszewski, Claudia Schmoor, Tobias Berg, Usama‐Ur Rehman, Marcus Schittenhelm, Katharina Götze, Andrea Kündgen, Caroline Pabst, Tobias Ma, Anna Frey, Julia Stomper, Dietmar Pfeifer, Eric Metzger, Johannes Jung, Kevin Moschallski, Johanna Thomas, Gesine Bug, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina, Michael Lübbert   +22 more
wiley   +1 more source

Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin [see comments] [PDF]

, 1993
RS Negrin, Ross S. Stein, J. W. Vardiman, Kathleen Doherty, Jordan Cornwell, Susan E. Krantz, PL Greenberg   +6 more
openalex   +1 more source

Efficacy and safety of luspatercept with or without erythropoiesis‐stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real‐life study by the GFM

British Journal of Haematology, EarlyView.
Maud D'Aveni, Laurence Schenone, Jose Miguel Torregrosa, Jean Pardo, Aspasia Stamatoullas, Colombe Saillard, Sylvain Thépot, Sophie Dimicoli, Clemence Santana, Etienne Daguindau, Francianne Paul, Lenaig Le Clech, Sophie Park, Thomas Cluzeau, Etienne Paubelle, Anne‐Laure Taksin‐Bressot, Fatiha Chermat, Lionel Adès, Pierre Fenaux, Thibault Comont   +19 more
wiley   +1 more source

Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry

European Journal of Haematology, EarlyView.
ABSTRACT VEXAS syndrome is caused by somatic mutations in the UBA1 gene and includes features of both autoinflammatory and myeloid diseases. Among several treatment options, JAK inhibitors have proven effective, especially ruxolitinib. However, anemia is often present in VEXAS syndrome.
Dominik Kiem, Michael Leisch, Ildiko Toth, Marie‐Christina Mayer, Lisa Pleyer, Richard Greil, Alexander Egle, Thomas Melchardt   +7 more
wiley   +1 more source

Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes [PDF]

, 1994
FA Asimakopoulos, NJ White, Elisabeth P. Nacheva, AR Green   +3 more
openalex   +1 more source

Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry

European Journal of Haematology, EarlyView.
ABSTRACT This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023).
Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vaneuza Araújo Moreira Funke, Anderson João, Nelson Hamerschlak, Neysimélia Costa Villela, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Aparecida Paz, Mariana Stevenazzi, Lilian Diaz, Abrahão Elias Hallack Neto, Gustavo Bettarello, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froes Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Eduardo José de Alencar Paton, Vanderson Geraldo Rocha, Alicia Enrico, Carmem Maria Sales Bonfim, Ricardo Chiattone, Celso Arrais‐Rodrigues, Erika Oliveira de Miranda Coelho, Marcelo Iastrebner, Beatrice Araújo Duarte, Vergílio Antônio Rensi Colturato   +29 more
wiley   +1 more source

Patient Characteristics, Healthcare Contacts and Drug Use in Polycythaemia Vera in Denmark

European Journal of Haematology, EarlyView.
ABSTRACT Objective Patients with polycythaemia vera (PV) may experience symptoms and cardiovascular complications before receiving a diagnosis. Understanding the associated patterns of healthcare and drug utilisation may help detect patients who need diagnostic workup.
Karoline Mathilde Lundgaard, Dustin Andersen Patel, Mette Brabrand, Christen Lykkegaard Andersen, Anton Pottegård   +4 more
wiley   +1 more source

Second‐ and Third‐Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML—A Population‐Based Study

European Journal of Haematology, EarlyView.
ABSTRACT Refractory acute myeloblastic leukemia (AML) is poorly studied. In this study, we characterized primary refractory AML and investigated treatment and outcome in a population‐based setting. Based on all AML patients receiving intensive induction therapy at 12 Swedish hospitals from 2011 to 2018 (N = 1221), we identified 306 patients that failed
Markus Liew‐Littorin, Linn Deleskog‐Spångberg, Stefan Deneberg, Judit Janosi, Vladimir Lazarevic, Gustav Nilsson, Aristea Papageorgiou, Anna Robelius, Lovisa Vennström, Gunnar Juliusson, Bertil Uggla, Martin Höglund, Sören Lehmann   +12 more
wiley   +1 more source

Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare [PDF]

, 1993
R Ohno, T Naoe, M Hirano, Miki Kobayashi, Hisamaru Hirai, Kazuo Tubaki, H Oh   +6 more
openalex   +1 more source